[go: up one dir, main page]

CA2265454A1 - Promedicaments peptidiques contenant une sequence de liaison alpha-hydroxyacide - Google Patents

Promedicaments peptidiques contenant une sequence de liaison alpha-hydroxyacide Download PDF

Info

Publication number
CA2265454A1
CA2265454A1 CA002265454A CA2265454A CA2265454A1 CA 2265454 A1 CA2265454 A1 CA 2265454A1 CA 002265454 A CA002265454 A CA 002265454A CA 2265454 A CA2265454 A CA 2265454A CA 2265454 A1 CA2265454 A1 CA 2265454A1
Authority
CA
Canada
Prior art keywords
peptide
glu
lys
alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002265454A
Other languages
English (en)
Inventor
Bjarne Due Larsen
Arne Holm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zealand Pharma AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2265454A1 publication Critical patent/CA2265454A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Promédicaments peptidiques de formule générale (I): X-L-Z, dans laquelle X représente une séquence peptidique pharmaceutiquement active, par ex. Leu-enképhaline; Z représente une pré-séquence peptidique comportant 2 à 20 motifs aminoacide, de préférence lysine et acide glutamique; et L représente un groupe de liaison comprenant 3 à 9 atomes du squelette, la liaison entre le carbonyle C-terminal de X et L étant différente de la liaison amide C-N. De préférence, la liaison entre X et L est une liaison ester. On a découvert qu'il était possible d'obtenir une augmentation remarquable de la résistance à la dégradation par des enzymes protéolytiques, par ex. carboxypeptidase A, pepsine A, leucine aminopeptidase, .alpha.-chymotrypsine, lorsqu'on masque un peptide pharmaceutiquement actif sous forme d'un promédicament de formule (I). Les promédicaments de formule (I) sont dissociés par l'enzyme de plasma sanguin, butyrylcholinestérase, ce qui indique une bonne bioréversibilité. La stabilité vis-à-vis de la dissociation enzymatique est vraisemblablement due à une structure hélicoïdale induite.
CA002265454A 1996-09-09 1997-09-09 Promedicaments peptidiques contenant une sequence de liaison alpha-hydroxyacide Abandoned CA2265454A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK0972/96 1996-09-09
DK97296 1996-09-09
PCT/DK1997/000376 WO1998011126A1 (fr) 1996-09-09 1997-09-09 Promedicaments peptidiques contenant une sequence de liaison alpha-hydroxyacide

Publications (1)

Publication Number Publication Date
CA2265454A1 true CA2265454A1 (fr) 1998-03-19

Family

ID=8099572

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002265454A Abandoned CA2265454A1 (fr) 1996-09-09 1997-09-09 Promedicaments peptidiques contenant une sequence de liaison alpha-hydroxyacide

Country Status (8)

Country Link
EP (1) EP0932614A1 (fr)
JP (1) JP2001505872A (fr)
KR (1) KR20000036015A (fr)
AU (1) AU724326B2 (fr)
CA (1) CA2265454A1 (fr)
IL (1) IL128828A0 (fr)
NZ (1) NZ334595A (fr)
WO (1) WO1998011126A1 (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035703A2 (fr) * 1997-02-14 1998-08-20 The Salk Institute For Biological Studies Procedes et compositions permettant d'apporter des agents therapeutiques a des tissus osseux a l'aide de conjugues d'oligomeres peptidiques charges negativement et d'agents therapeutiques
CA2321026A1 (fr) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Conjugues peptidiques pharmacologiquement actifs ayant une tendance reduite a l'hydrolyse enzymatique
EP1076066A1 (fr) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US7671029B2 (en) 1999-08-06 2010-03-02 Immupharma Sa Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances
US6908900B2 (en) 2001-01-17 2005-06-21 Zimmer & Associates Ag Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients
US6939693B2 (en) 1999-10-29 2005-09-06 Novus International, Inc. Enantioselective oligomerization of α-hydroxy carboxylic acids and α-amino acids
WO2001032906A2 (fr) * 1999-10-29 2001-05-10 Novus International, Inc. OLIGOMERES ET SEGMENTS OLIGOMERES D'ACIDES α-HYDROXYCARBOXYLIQUES ET D'ACIDES α-AMINES
DE10018617A1 (de) * 2000-01-13 2001-10-31 Joerg G Moser Cyclodextrin-Dimere mit Peptid-Spacerstrukturen zur Entgiftung von pharmazeutischen Wirkstoffen hohen Nebenwirkungspotentials
JP4334866B2 (ja) 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
US6881829B2 (en) * 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
DK1745078T3 (da) 2004-04-23 2009-10-26 Conjuchem Biotechnologies Inc Fremgangsmåde til oprensning af albuminkonjugater
EP1934245B1 (fr) 2005-09-21 2011-07-13 7TM Pharma A/S Agonistes selectifs du recepteur y2 pour applications therapeutiques
CN101268099A (zh) 2005-09-21 2008-09-17 7Tm制药联合股份有限公司 用于治疗性干预的y4选择性受体激动剂
CA2628241C (fr) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
SG177953A1 (en) 2007-01-05 2012-02-28 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
CA3128656A1 (fr) 2007-08-22 2009-02-26 The Regents Of The University Of California Polypeptides de liaison activables et procedes d'identification et utilisation de ceux-ci
US8981047B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Glucagon antagonists
CA2702289A1 (fr) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Composes presentant une activite d'antagoniste de glucagon et d'agoniste du glp-1
JP2011511778A (ja) 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
BRPI0915282A2 (pt) 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
EP2307037A4 (fr) 2008-06-17 2011-08-03 Univ Indiana Res & Tech Corp Analogues de glucagon présentant des tampons de ph physiologique présentant une solubilité et une stabilité améliorées
CA2728284C (fr) 2008-06-17 2019-09-10 Richard D. Dimarchi Co-agonistes du recepteur glucagon/glp-1
PL2370462T3 (pl) 2008-12-15 2015-01-30 Zealand Pharma As Analogi glukagonu
US8642540B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
MX2011006313A (es) 2008-12-15 2011-09-27 Zealand Pharma As Analogos de glucagon.
PL2370461T3 (pl) 2008-12-15 2014-03-31 Zealand Pharma As Analogi glukagonu
AR074811A1 (es) 2008-12-19 2011-02-16 Univ Indiana Res & Tech Corp Profarmaco de peptido de la superfamilia de glucagon basados en amida
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US9156901B2 (en) 2009-07-13 2015-10-13 Ditte Riber Acylated glucagon analogues
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CN102834108A (zh) 2010-01-27 2012-12-19 印第安纳大学研究及科技有限公司 用于治疗代谢紊乱和肥胖症的胰高血糖素拮抗剂-gip激动剂偶联物和组合物
WO2011134471A1 (fr) 2010-04-27 2011-11-03 Zealand Pharma A/S Conjugués peptidiques d'antagonistes du récepteur de glp-1 et de gastrine, et leur utilisation
EP2569000B1 (fr) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Peptides de la superfamille des glucagons présentant une activité de récepteur nucléaire d'hormone
KR20130111923A (ko) 2010-05-13 2013-10-11 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
AU2011268327B2 (en) 2010-06-16 2016-02-25 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
EP2585102B1 (fr) 2010-06-24 2015-05-06 Indiana University Research and Technology Corporation Promédicaments insuliniques à base d'amide
AU2011269430A1 (en) 2010-06-24 2013-01-10 Zealand Pharma A/S Glucagon analogues
CA2796894A1 (fr) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Promedicaments peptidiques a base d'amides de la superfamille du glucagon
WO2012088116A2 (fr) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Analogues du glucagon présentant une activité de récepteur de gip
PH12013502671A1 (en) 2011-06-22 2022-04-08 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
EP2723766A4 (fr) 2011-06-22 2015-05-20 Univ Indiana Res & Tech Corp Co-agonistes du récepteur du glucagon et du récepteur du gpl-1
CA2843506C (fr) * 2011-08-12 2020-05-12 Ascendis Pharma A/S Promedicaments relies a des supports comprenant des liaisons ester carboxylique reversibles
CN104144704B (zh) 2011-11-03 2018-03-23 西兰制药公司 Glp‑1受体激动剂肽胃泌素缀合物
US8859491B2 (en) 2011-11-17 2014-10-14 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
WO2013096386A1 (fr) 2011-12-20 2013-06-27 Indiana University Research And Technology Corporation Analogues d'insuline à base de ctp pour le traitement du diabète
CA2871458C (fr) 2012-04-27 2020-06-23 Cytomx Therapeutics, Inc. Anticorps activables liant le recepteur du facteur de croissance epidermique et leurs procedes d'utilisation
IN2014MN02304A (fr) 2012-05-03 2015-08-07 Zealand Pharma As
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
CN109456400A (zh) 2012-07-23 2019-03-12 西兰制药公司 胰高血糖素类似物
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014052451A2 (fr) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Dimères analogues de l'insuline
CN104936613B (zh) 2012-11-30 2018-05-22 株式会社糖锁工学研究所 糖链加成连接子、含有糖链加成连接子与生理活性物质的化合物或其盐、以及其制造方法
US20160024169A1 (en) 2013-03-14 2016-01-28 Indiana University Research And Technology Corporation Insulin-incretin conjugates
EP2976331B1 (fr) 2013-03-21 2017-03-01 Sanofi-Aventis Deutschland GmbH Synthèse de produits peptidiques contenant de l'hydantoïne
HUE033371T2 (en) 2013-03-21 2017-11-28 Sanofi Aventis Deutschland Process for the preparation of peptide products containing a ring imide
HUE039949T2 (hu) * 2013-05-07 2019-02-28 Merck Patent Gmbh Konjugátum nefrotoxikus hatóanyagoktól történõ védelemre
EP2994153B1 (fr) * 2013-05-07 2018-08-15 Merck Patent GmbH Peptides et conjugués peptide-principe actif pour ciblage rénal
RS57632B1 (sr) 2013-10-17 2018-11-30 Zealand Pharma As Acilovani analozi glukagona
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
CN105849122B (zh) 2013-11-06 2021-04-30 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
JP2017503474A (ja) 2013-11-06 2017-02-02 ジーランド ファーマ アクティーゼルスカブ グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
WO2015089283A1 (fr) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Anticorps qui se lient à des anticorps activables et leurs procédés d'utilisation
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
JP6701208B2 (ja) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 脂質化アミド系インスリンプロドラッグ
TWI705973B (zh) 2014-10-29 2020-10-01 丹麥商西蘭製藥公司 Ｇｉｐ促效劑化合物及方法
PL3283507T3 (pl) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylowany analog glukagonu
EP3551651B1 (fr) 2016-12-09 2024-03-06 Zealand Pharma A/S Doubles agonistes glp-1/glp-2 acylés
AU2018368769B2 (en) 2017-11-17 2024-05-09 Cytogel Pharma, Llc Polymer agonists of mu opioid receptors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589356A (en) * 1993-06-21 1996-12-31 Vanderbilt University Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement

Also Published As

Publication number Publication date
AU724326B2 (en) 2000-09-14
NZ334595A (en) 2000-08-25
AU4199497A (en) 1998-04-02
KR20000036015A (ko) 2000-06-26
EP0932614A1 (fr) 1999-08-04
WO1998011126A1 (fr) 1998-03-19
JP2001505872A (ja) 2001-05-08
IL128828A0 (en) 2000-01-31

Similar Documents

Publication Publication Date Title
CA2265454A1 (fr) Promedicaments peptidiques contenant une sequence de liaison alpha-hydroxyacide
US4737487A (en) VIP type peptides
AU757658B2 (en) Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
AU612054B2 (en) Peptides having bradykinin antagonist action
JP2726647B2 (ja) 環状ペプチドおよびその用途
US4277394A (en) Tetrapeptidehydrazide derivatives
RU2081880C1 (ru) Производные пептидов
EP0037516B1 (fr) Dérivés N-omega substituées des analogues de 1-Desamino-vasopressin
JPS62116595A (ja) 新規化合物、その製法及びそれを含む医薬組成物
Fruchart et al. A new linker for the synthesis of C-terminal peptide α-oxo-aldehydes
HU185321B (en) Process for preparing pharmacologically active ancephaline analogues
JP2949129B2 (ja) 胃腸運動刺激活性を有するモチリン類似ポリペプチド
JPH10503216A (ja) Ｎα−２−（４−ニトロフェニルスルフォニル）エトキシカルボニル−アミノ酸
HU217613B (hu) Az N-terminálison módosított peptidek, az azokat tartalmazó gyógyszerkészítmények és eljárás előállításukra
JPH0592996A (ja) 心房性ナトリウム利尿因子活性をもつペプチド
JP2011507821A (ja) ペプチド修飾の方法
US6051685A (en) Peptide derivatives
HU177134B (en) Process for preparing angiotensin ii analogues containing alpha-hydroxy-acid in position 1 with angiotensin ii antagonist activity
US4829051A (en) N-substituted derivatives of 1-desaminovasopressin
MXPA99002149A (en) Peptide prodrugs containing an alpha-hydroxyacid linker
WO1986003495A2 (fr) Derives des substances p et de leurs fragments
CA1180006A (fr) Pseudopeptides a action therapeutique, composes les contenant et methode de preparation et d'utilisation
JPH0135839B2 (fr)
WO1992012170A1 (fr) Inhibitions de formulation d'endotheline
JPH038360B2 (fr)

Legal Events

Date Code Title Description
FZDE Discontinued